Potential applications for biguanides in oncology

Area of Science:

• Oncology
• Pharmacology
• Endocrinology

Background:

• Metformin is a first-line medication for type II diabetes.
• Emerging research suggests biguanides, including metformin, possess antineoplastic properties.
• The anticancer mechanisms may involve direct effects on cancer cells or indirect modulation of the tumor microenvironment.

Purpose of the Study:

• To review the proposed antineoplastic mechanisms of metformin and related biguanides.
• To evaluate the role of drug exposure levels in direct anticancer effects.
• To assess the significance of metformin-induced systemic changes for therapeutic benefit.

Main Methods:

• Review of preclinical data on biguanide antineoplastic activity.
• Analysis of proposed direct and indirect mechanisms of action.
• Evaluation of metformin's impact on systemic mediators like insulin and cytokines.
• Monitoring of ongoing clinical trials.

Main Results:

• Preclinical evidence indicates that drug concentration is critical for direct antineoplastic effects.
• Metformin influences systemic mediators, but the therapeutic relevance of these changes requires further investigation.
• First-generation clinical trials are in progress, with results eagerly awaited.

Conclusions:

• Metformin's antineoplastic potential warrants further investigation.
• Future research should focus on optimizing metformin's use in cancer therapy through pharmacokinetic studies, combination therapies, and biomarker identification.
• Novel biguanides and synthetic lethality approaches may enhance therapeutic efficacy.